Pfizer Inc. (NYSE:PFE) Shares Purchased by Cary Street Partners Asset Management LLC

Cary Street Partners Asset Management LLC increased its position in shares of Pfizer Inc. (NYSE:PFE) by 7.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,865 shares of the biopharmaceutical company’s stock after acquiring an additional 1,238 shares during the period. Cary Street Partners Asset Management LLC’s holdings in Pfizer were worth $546,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. purchased a new stake in Pfizer during the 1st quarter worth about $315,000. Central Pacific Bank Trust Division purchased a new position in shares of Pfizer in the 1st quarter valued at about $136,000. GSA Capital Partners LLP purchased a new position in shares of Pfizer in the 1st quarter valued at about $439,000. Disciplined Equity Management Inc. increased its holdings in shares of Pfizer by 2,676.8% in the 1st quarter. Disciplined Equity Management Inc. now owns 66,920 shares of the biopharmaceutical company’s stock valued at $1,857,000 after acquiring an additional 64,510 shares during the last quarter. Finally, Broderick Brian C increased its holdings in shares of Pfizer by 382.9% in the 1st quarter. Broderick Brian C now owns 34,550 shares of the biopharmaceutical company’s stock valued at $959,000 after acquiring an additional 27,396 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Activity at Pfizer

In other news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $282,400. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent analyst reports. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. UBS Group increased their price objective on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Sanford C. Bernstein initiated coverage on Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target on the stock. Finally, Barclays raised their price target on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $33.58.

Pfizer Stock Performance

Pfizer stock opened at $27.98 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The stock has a fifty day moving average of $28.99 and a two-hundred day moving average of $28.65. The company has a market capitalization of $158.55 billion, a price-to-earnings ratio of 37.81, a PEG ratio of 0.89 and a beta of 0.67. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.17) earnings per share. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.00%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is currently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.